Prognostic factors for renal cell carcinoma with tumor thrombus extension

We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved. We studied clinicopathological parameters in 321 consecutive patients who were surgically treated for renal cell carcinoma with tumor thrombus...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of urology Vol. 178; no. 4 Pt 1; p. 1189
Main Authors Klatte, Tobias, Pantuck, Allan J, Riggs, Stephen B, Kleid, Mark D, Shuch, Brian, Zomorodian, Nazy, Kabbinavar, Fairooz F, Belldegrun, Arie S
Format Journal Article
LanguageEnglish
Published United States 01.10.2007
Subjects
Online AccessGet more information

Cover

Loading…
Abstract We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved. We studied clinicopathological parameters in 321 consecutive patients who were surgically treated for renal cell carcinoma with tumor thrombus extension. Disease specific survival was evaluated with univariate and multivariate analysis. Harrell's C-index was used to assess the prognostic accuracy of prognostic models. Tumor thrombus extended into the renal vein in 166 patients, the inferior vena cava in 137 and the atrium in 18. Metastatic renal cell carcinoma was found in 198 patients (62%). The thrombus level had no impact on clinicopathological parameters or survival but perioperative morbidity and mortality increased with cranial extension of the thrombus. Mean followup was 49 months. Five and 10-year disease specific survival rates were 36% and 24%, respectively. On multivariate analysis Eastern Cooperative Oncology Group performance status, lymph node and distant metastases, sarcomatoid features and perinephric fat invasion were independent prognostic factors. Weight loss, anemia, collecting system invasion, incomplete surgical resection, nuclear grade and T classification were also significant prognosticators on univariate analysis. For patients with advanced disease the number of metastatic sites and the disease-free interval further predicted prognosis. The overall immunotherapy response rate was 19%, which decreased with cranial extension of the thrombus. Redefinition of the T3 classification with the incorporation of fat invasion improved prognostic accuracy, as shown by an increase in the C-index. Eastern Cooperative Oncology Group performance status, metastatic status, sarcomatoid features and concomitant perinephric fat invasion are the most powerful prognostic factors of survival in renal cell carcinoma with tumor thrombus extension. Our data indicate that a redefinition of the current T3 classification may improve its predictive accuracy. We propose that T3 renal cell carcinoma with fat invasion or thrombus extension alone should be classified as T3a, while that with thrombus extension plus fat invasion should be classified as T3b.
AbstractList We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved. We studied clinicopathological parameters in 321 consecutive patients who were surgically treated for renal cell carcinoma with tumor thrombus extension. Disease specific survival was evaluated with univariate and multivariate analysis. Harrell's C-index was used to assess the prognostic accuracy of prognostic models. Tumor thrombus extended into the renal vein in 166 patients, the inferior vena cava in 137 and the atrium in 18. Metastatic renal cell carcinoma was found in 198 patients (62%). The thrombus level had no impact on clinicopathological parameters or survival but perioperative morbidity and mortality increased with cranial extension of the thrombus. Mean followup was 49 months. Five and 10-year disease specific survival rates were 36% and 24%, respectively. On multivariate analysis Eastern Cooperative Oncology Group performance status, lymph node and distant metastases, sarcomatoid features and perinephric fat invasion were independent prognostic factors. Weight loss, anemia, collecting system invasion, incomplete surgical resection, nuclear grade and T classification were also significant prognosticators on univariate analysis. For patients with advanced disease the number of metastatic sites and the disease-free interval further predicted prognosis. The overall immunotherapy response rate was 19%, which decreased with cranial extension of the thrombus. Redefinition of the T3 classification with the incorporation of fat invasion improved prognostic accuracy, as shown by an increase in the C-index. Eastern Cooperative Oncology Group performance status, metastatic status, sarcomatoid features and concomitant perinephric fat invasion are the most powerful prognostic factors of survival in renal cell carcinoma with tumor thrombus extension. Our data indicate that a redefinition of the current T3 classification may improve its predictive accuracy. We propose that T3 renal cell carcinoma with fat invasion or thrombus extension alone should be classified as T3a, while that with thrombus extension plus fat invasion should be classified as T3b.
Author Zomorodian, Nazy
Kleid, Mark D
Klatte, Tobias
Shuch, Brian
Belldegrun, Arie S
Riggs, Stephen B
Pantuck, Allan J
Kabbinavar, Fairooz F
Author_xml – sequence: 1
  givenname: Tobias
  surname: Klatte
  fullname: Klatte, Tobias
  organization: Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California 90095-1738, USA
– sequence: 2
  givenname: Allan J
  surname: Pantuck
  fullname: Pantuck, Allan J
– sequence: 3
  givenname: Stephen B
  surname: Riggs
  fullname: Riggs, Stephen B
– sequence: 4
  givenname: Mark D
  surname: Kleid
  fullname: Kleid, Mark D
– sequence: 5
  givenname: Brian
  surname: Shuch
  fullname: Shuch, Brian
– sequence: 6
  givenname: Nazy
  surname: Zomorodian
  fullname: Zomorodian, Nazy
– sequence: 7
  givenname: Fairooz F
  surname: Kabbinavar
  fullname: Kabbinavar, Fairooz F
– sequence: 8
  givenname: Arie S
  surname: Belldegrun
  fullname: Belldegrun, Arie S
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17698087$$D View this record in MEDLINE/PubMed
BookMark eNo1j8tKAzEYRrOo2Iu-gAvJC8z4_5lMMllK8VIo6ELXJckkdkonKUkG9e0tqJvvLA4c-JZkFmJwhNwg1Ago7g71YUqxZgCyhrbGhs_IAoCxqm24nJNlzgcA5K1kl2SOUqgOOrkgm9cUP0LMZbDUa1tiytTHRJML-kitO55HJzuEOGr6OZQ9LdN49mWf4mimTN1XcSEPMVyRC6-P2V3_cUXeHx_e1s_V9uVps77fVpaDKhVXLfMSnNGuNxYECsW1NNwb2_caOQqOKBupvGqFVlYK49B3vEPQoLljK3L72z1NZnT97pSGUafv3f8n9gNHsFCL
CitedBy_id crossref_primary_10_1016_j_jns_2015_06_006
crossref_primary_10_1016_j_urolonc_2010_11_017
crossref_primary_10_1007_s11934_014_0451_0
crossref_primary_10_15591_mtp_2015_034
crossref_primary_10_1007_s12094_019_02136_5
crossref_primary_10_1016_j_urolonc_2014_11_015
crossref_primary_10_1097_CAD_0000000000000627
crossref_primary_10_3390_jcm10173852
crossref_primary_10_1053_j_jvca_2013_04_002
crossref_primary_10_1055_a_0919_4043
crossref_primary_10_1155_2017_3142926
crossref_primary_10_1111_bju_12515
crossref_primary_10_1111_j_1464_410X_2009_08489_x
crossref_primary_10_1186_1752_1947_5_245
crossref_primary_10_1111_j_1464_410X_2008_07660_x
crossref_primary_10_1016_j_eururo_2011_05_029
crossref_primary_10_1016_j_juro_2008_10_040
crossref_primary_10_1007_s00345_014_1276_7
crossref_primary_10_7134_phlebol_21_3_241
crossref_primary_10_1097_MD_0000000000030808
crossref_primary_10_1007_s11912_008_0036_5
crossref_primary_10_1093_jjco_hyaa275
crossref_primary_10_1016_j_juro_2010_04_071
crossref_primary_10_1016_j_acuro_2016_06_007
crossref_primary_10_1186_s13256_024_04517_z
crossref_primary_10_1089_end_2015_0492
crossref_primary_10_1586_14737140_2013_858603
crossref_primary_10_1007_s00432_014_1703_6
crossref_primary_10_1089_cbr_2020_3948
crossref_primary_10_1186_s40644_022_00502_1
crossref_primary_10_1053_j_jvca_2017_02_036
crossref_primary_10_1016_j_juro_2013_02_033
crossref_primary_10_1111_j_1464_410X_2010_09937_x
crossref_primary_10_1016_j_cpccr_2022_100180
crossref_primary_10_1016_j_critrevonc_2011_02_003
crossref_primary_10_1111_j_1442_2042_2008_02062_x
crossref_primary_10_1186_1756_0500_5_264
crossref_primary_10_1016_j_eururo_2011_02_032
crossref_primary_10_1155_2015_163423
crossref_primary_10_1155_2013_546709
crossref_primary_10_7863_ultra_15_10038
crossref_primary_10_1007_s00345_014_1449_4
crossref_primary_10_1002_iju5_12668
crossref_primary_10_1016_j_urolonc_2021_08_016
crossref_primary_10_1586_era_12_142
crossref_primary_10_1007_s10147_017_1232_9
crossref_primary_10_1016_j_eururo_2013_06_048
crossref_primary_10_1038_srep21325
crossref_primary_10_1016_j_urolonc_2009_09_018
crossref_primary_10_1007_s11255_012_0314_x
crossref_primary_10_1111_j_1442_2042_2011_02893_x
crossref_primary_10_1111_j_1464_410X_2010_09488_x
crossref_primary_10_5867_medwave_2016_06_6494
crossref_primary_10_1111_iju_12012
crossref_primary_10_1016_S0210_4806_09_74162_2
crossref_primary_10_1200_JCO_2017_75_4242
crossref_primary_10_1371_journal_pone_0109877
crossref_primary_10_1016_j_juro_2014_05_065
crossref_primary_10_47572_muskutd_874391
crossref_primary_10_1016_j_aju_2011_12_007
crossref_primary_10_3233_KCA_190071
crossref_primary_10_1186_s12894_016_0157_3
crossref_primary_10_1016_j_eururo_2010_10_001
crossref_primary_10_17650_1726_9776_2021_17_3_19_28
crossref_primary_10_2214_AJR_14_13802
crossref_primary_10_1016_j_eururo_2008_07_053
crossref_primary_10_1111_ans_13272
crossref_primary_10_1097_CAD_0000000000000422
crossref_primary_10_1590_S1677_5538_IBJU_2013_03_08
crossref_primary_10_1016_j_urology_2010_02_047
crossref_primary_10_1111_iju_14943
crossref_primary_10_1186_1471_2407_13_447
crossref_primary_10_2214_AJR_10_4688
crossref_primary_10_3389_fonc_2022_980564
crossref_primary_10_1111_j_1464_410X_2012_11498_x
crossref_primary_10_1016_j_avsg_2021_05_036
crossref_primary_10_3390_cancers15071981
crossref_primary_10_1111_iju_13293
crossref_primary_10_1038_modpathol_2008_183
crossref_primary_10_1111_j_1464_410X_2012_11174_x
crossref_primary_10_1080_21681805_2016_1217558
crossref_primary_10_1038_s41416_023_02166_5
crossref_primary_10_1111_j_1464_410X_2008_07917_x
crossref_primary_10_3892_mmr_2017_6136
crossref_primary_10_1080_14737140_2018_1431530
crossref_primary_10_1111_bju_12322
crossref_primary_10_1016_j_ejso_2012_03_006
crossref_primary_10_1016_j_juro_2014_03_112
crossref_primary_10_1016_j_ctrv_2018_06_014
crossref_primary_10_1093_jjco_hyu072
crossref_primary_10_5758_vsi_230056
crossref_primary_10_1016_j_juro_2014_03_111
crossref_primary_10_1186_s12885_019_5359_0
crossref_primary_10_1007_s13691_024_00657_7
crossref_primary_10_1007_s13304_020_00806_6
crossref_primary_10_1007_s11934_011_0222_0
crossref_primary_10_1111_jth_12580
crossref_primary_10_1111_j_1464_410X_2011_10366_x
crossref_primary_10_1016_j_acuroe_2016_12_008
crossref_primary_10_1111_iju_13272
crossref_primary_10_1111_bju_13268
crossref_primary_10_1111_j_1464_410X_2009_08484_x
crossref_primary_10_1002_cam4_2775
crossref_primary_10_1007_s00345_008_0358_9
crossref_primary_10_1016_j_urolonc_2015_04_010
crossref_primary_10_22465_juo_234600600030
crossref_primary_10_32948_auo_2018_11_1
crossref_primary_10_1111_iju_12738
crossref_primary_10_1016_j_ucl_2008_07_013
crossref_primary_10_4111_kju_2009_50_2_105
crossref_primary_10_1007_s11255_012_0168_2
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1016/j.juro.2007.05.134
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 17698087
Genre Journal Article
GroupedDBID ---
--K
.55
.GJ
.XZ
08P
0R~
123
1B1
1CY
354
3O-
4.4
457
4G.
4Q1
4Q2
4Q3
53G
5RE
5VS
7-5
AAAAV
AAEDT
AAEDW
AAGIX
AAHPQ
AAIQE
AAJCS
AAKAS
AALRI
AAMOA
AAQFI
AAQKA
AAQQT
AAQXK
AASCR
AASXQ
AAXUO
ABASU
ABCQX
ABDIG
ABJNI
ABLJU
ABMAC
ABOCM
ABPPZ
ABVCZ
ACGFS
ACILI
ACOAL
ACXJB
ADGGA
ADHPY
ADMUD
ADNKB
ADPAM
ADZCM
AEBDS
AEETU
AENEX
AFDTB
AFEXH
AFFNX
AFTRI
AFUWQ
AGHFR
AHOMT
AHQNM
AHRYX
AHVBC
AI.
AINUH
AITUG
AIZYK
AJIOK
AJNWD
AJZMW
AKULP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AMRAJ
ASGHL
ASPBG
AVWKF
AZFZN
BCGUY
BELOY
BYPQX
C45
C5W
CGR
CS3
CUY
CVF
DIWNM
DU5
EBS
ECM
EEVPB
EIF
EJD
ERAAH
EX3
F5P
FCALG
FDB
FEDTE
FGOYB
GBLVA
GNXGY
GQDEL
HLJTE
HVGLF
HZ~
H~9
IH2
IHE
IKREB
IKYAY
IPNFZ
J5H
KMI
L7B
M41
MJL
MO0
N4W
NPM
NQ-
NTWIH
O9-
OAG
OAH
OB3
OBH
ODMTH
OGROG
OHH
OL1
OVD
OWU
OWV
OWW
OWY
OWZ
P2P
QTD
R2-
RIG
RLZ
ROL
RPZ
SEL
SES
SJN
SSZ
TEORI
TSPGW
UDS
UNMZH
UV1
VH1
VVN
WOW
X7M
XH2
XYM
YFH
YOC
ZCG
ZFV
ZGI
ZXP
ZY1
ZZMQN
ID FETCH-LOGICAL-c409t-4952f70ebaedbc061694a7b4fbcdda14164117379f956a9c76be1f84810a0a4e2
ISSN 0022-5347
IngestDate Sat Sep 28 07:52:00 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4 Pt 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c409t-4952f70ebaedbc061694a7b4fbcdda14164117379f956a9c76be1f84810a0a4e2
PMID 17698087
ParticipantIDs pubmed_primary_17698087
PublicationCentury 2000
PublicationDate 2007-10-01
PublicationDateYYYYMMDD 2007-10-01
PublicationDate_xml – month: 10
  year: 2007
  text: 2007-10-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of urology
PublicationTitleAlternate J Urol
PublicationYear 2007
SSID ssj0014572
Score 2.3254972
Snippet We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved....
SourceID pubmed
SourceType Index Database
StartPage 1189
SubjectTerms Aged
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - surgery
Chemotherapy, Adjuvant
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Interferon-alpha - therapeutic use
Interleukin-2 - therapeutic use
Kidney - pathology
Kidney Neoplasms - drug therapy
Kidney Neoplasms - mortality
Kidney Neoplasms - pathology
Kidney Neoplasms - surgery
Lymphatic Metastasis
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness - pathology
Neoplasm Staging
Neoplastic Cells, Circulating
Prognosis
Retrospective Studies
Survival Analysis
Title Prognostic factors for renal cell carcinoma with tumor thrombus extension
URI https://www.ncbi.nlm.nih.gov/pubmed/17698087
Volume 178
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBbJCmUvY-3WtVtb9NC34GA5smU_lrHRriSE0kLegmRLkJDYxU0o7K_fnSX_aOhGuxdjLDC2v8_nu_Pdd4RciEhF0teRJxhLPC6yzFMBg8A1M8xkBiJnjc3J40l0dc9_zcJZr_fU7S7ZqGH6-8W-kv9BFY4Brtgl-wZkm5PCAdgHfGELCMP2VRhPywLr5FBztZ6bg1WDpUYXE1PyKDydLvJiLV3CdbuuqgrLYq22j4MqA_5YI7NsidNxU7fls8T7zQoFOSuUC7WQjUc-BYS21rReArPy9nfTbZ1-dwVl7Zznm5VeZHXDkCs9rhMQoill6zYEhCMrnNkYVRF32MMH082AdewkhDXJiwbc5hKWwyXcnROYDIfM5js7iD6sK0iZiJLYt1_sf6_uiGrXS33SFzEaxgkmedzPJx6KRmQe78v1WtmywN0LQ9VZd7KdyKTyUO4-kg8OM3ppeXJAejo_JPtjVzzxiVy3dKGOLhToQiu6UKQLbehCkS60ogut6UIbunwm9z9_3H2_8twkDS-F-H3jQRQcGOFrJXWmUnDhooRLobhRaZZJBk45Z0yMRGIgXJZJCm-wZgYnLfjSl1wHR-RdXuT6mFCDIoJBwo3GkfAmkpEJwjiNUz4C5zwcnZAv9iHMH6xcyrx-PF__uvKNvG-JdUr2DLyf-gycvY06r6D5A1YLUmU
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+factors+for+renal+cell+carcinoma+with+tumor+thrombus+extension&rft.jtitle=The+Journal+of+urology&rft.au=Klatte%2C+Tobias&rft.au=Pantuck%2C+Allan+J&rft.au=Riggs%2C+Stephen+B&rft.au=Kleid%2C+Mark+D&rft.date=2007-10-01&rft.issn=0022-5347&rft.volume=178&rft.issue=4+Pt+1&rft.spage=1189&rft_id=info:doi/10.1016%2Fj.juro.2007.05.134&rft_id=info%3Apmid%2F17698087&rft_id=info%3Apmid%2F17698087&rft.externalDocID=17698087
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-5347&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-5347&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-5347&client=summon